Earnings

Direct seller's going to need more than larger number of distributors to generate sustainable growth, analysts say.

Firm’s future, as a separate business nearly 90% owned by Bausch Health, or as a standalone with different ownership or one not controlled by a majority owner, claims high profile in analysts’ comments and predictions. B+L is in the driver’s seat, they say.

Haleon highlighted consistent market share gains in China as it reported third-quarter results.

A better than expected showing from its Health business in its latest quarter has teed up Reckitt for a big finish to the year.

Major Europe-based consumer health players Sanofi, Haleon, Reckitt and Bayer feature in this sales and earnings preview, which highlights what to look out for as these four firms report their Q3 2024 results over the coming weeks.

Nestlé's US dietary supplement brands are beginning to take back market share a year on from a IT malfunction which has proved harder to recover from than first expected.

An end to litigation filed by institutional investors, insurance companies and pension funds comes four CEOs after Perrigo's chief exec during Mylan's tender in 2015, Joseph Papa, resigned to lead another firm in 2016. Plaintiff attorneys are asking for up to 20% of settlement in fees.

Intensified competition in the dietary supplements market and consumers squeezed by cost-of-living pressures held back sales at Dermapharm's Arkopharma subsidiary in the first half. A leadership change, along with a renewed focus on commercial excellence, is hoped by Dermapharm to turn the business around.

OTC erectile dysfunction treatment Eroxon has made it to the Nordics through local distributor Navamedic, which has reported strong consumer uptake.

OTC sales edged up at Italy's Recordati in the first half of 2024 as higher demand for GI products and supplements offset a weaker cold & flu season.

Herbalife adds distributors and training as sales slow; Amphastar bullish on Primatene Mist $100M full-year target; and ChromaDex net sales up 12%.

Plant-based digestive health remedy Iberogast, alongside Bepanthen Derma and Supradyn dietary supplements, are the brands currently driving sales growth at Bayer Consumer Health, according to the firm's Q2 financial report.

Kenvue maintains full-year guidance after 0.3% Q2 net sales dip beat market expectations. Essential health segment alone drove sales; self-care and skin health/beauty faltered. US sales of Neutrogena Collagen Bank pre-aging platform launched on TikTok shop, a first for the brand.

Church & Dwight’s slower sales at retail in June-July than in January-May point to still slower results for rest of year. It doesn’t expect second-half help from gummy vitamin lines or give them a full vote of confidence for remaining in portfolio.

OTC private label/store brand product giant’s Q2 net sales down 10.7% to $1.1bn, but women’s health product sales jump 31.4% largely on Opill launched late in Q1. Biggest hit to results from infant formula business, down a reported 82% due to ongoing manufacturing quality-control remediation.

Haleon has begun reformulating phenylephrine-containing oral decongestants marketed in the US as the company looks to get ahead of an anticipated FDA decision on the ingredient's use in OTC cough and cold products. The UK-based consumer health manufacturer revealed its plan as it reported organic sales up 3.5% in the first half of 2024.

Brimonidine tartrate eye drops remain key sales driver among Canadian firm’s consumer health lines with 12% growth in the latest quarter. B+L expects pending launch of preservative-free line extension to sustain Lumify as a driver as generics of original formulation are approved.

Strong uptake of its innovative plant-based omega-3 products is helping to drive an increase in dietary supplements sales for ingredients supplier DSM-Firmenich.

P&G's FY2024 Q4 net sales were flat at $20.5bn, lower than consensus estimates, but the firm says its underlying business divisions are healthy and forecasts FY2025 sales up 2% to 4%, up 3% to 5% organically.

Unilever hopes to double the value of its product innovations this year, ultimately targeting as many as 12 innovations, each costing more than €100m, beginning in 2025, CEO Hein Schumacher says during 25 July earnings presentation.